pd-0360324
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00550355)
Timeline
Indications
Mechanism of action
CSF1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pd 0360324
- pd-0360324
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02948101 | Phase 2 | Dec 1, 2016 | Pfizer, University of Texas at Houston |
| NCT02554812 | Phase 2 | Nov 1, 2015 | Pfizer |
| NCT01732211 | Phase 2 | Mar 1, 2013 | Pfizer |
| NCT01470313 | Phase 1 | Nov 1, 2011 | Pfizer |
| NCT00550355 | Phase 1 | Aug 1, 2007 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 4 | 2 | 2007 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1